Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immix Biopharma Inc IMMX

Healthcare Biotechnology
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being... see more

Recent & Breaking News (NDAQ:IMMX)

Immix Biopharma on Track to Dose NXC-201 Patients in United States

GlobeNewswire 1 day ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

GlobeNewswire 4 days ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

GlobeNewswire March 20, 2024

Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative

GlobeNewswire March 5, 2024

Immix Biopharma 12 Month Review Progress Update

GlobeNewswire February 21, 2024

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

GlobeNewswire February 8, 2024

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

GlobeNewswire February 7, 2024

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

GlobeNewswire February 5, 2024

Immix Biopharma Announces Proposed Public Offering of Common Stock

GlobeNewswire February 5, 2024

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

GlobeNewswire January 24, 2024

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

GlobeNewswire January 4, 2024

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

GlobeNewswire December 18, 2023

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

GlobeNewswire December 11, 2023

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

GlobeNewswire November 30, 2023

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

GlobeNewswire November 22, 2023

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

GlobeNewswire November 21, 2023

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

GlobeNewswire November 6, 2023

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

GlobeNewswire November 6, 2023

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

GlobeNewswire October 26, 2023

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

GlobeNewswire October 16, 2023